Brief: Simcere Pharmaceutical Posts HY Net Income Attributable Of RMB 829 MLN
20/08/2026 15:55
BRIEF-Simcere Pharmaceutical Posts HY Net Income Attributable Of RMB 829 MLN Aug 20 (Reuters) - Simcere Pharmaceutical Group H1 net income attributable RMB 829 million.
- H1 revenue RMB 4,580 million
- REN JINSHENG WILL SERVE AS CHIEF EXECUTIVE OFFICER
- DR. ZHOU WILL SERVE AS PRESIDENT
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660